The ‘false promise’ of chemotherapy in treating cancer.
This is the first place, anywhere in the world, where such a significant amount of evidence exposing the fraud of chemotherapy has been amassed. We don’t feel that science supports the use of chemo. This is why we broke ranks with our colleagues to demonstrate the truth as we see it. We believe that rational people interested in the truth will evaluate the evidence and conclude the same.
We’ve been waiting for science to do more than just smugly state its superiority by actually putting aitself into an objective evaluation, and we’re still waiting.
Think about how brainwashed conventionally-trained oncologists have become. They actually believe that cancer therapies are “working” when a person loses their appetite, muscle strength, hair, body weight and immune function, as long as the poisonous drugs they give are shrinking a tumor. The quality of life issues for patients are secondary. Does that sound right to you? How can “responses” (temporary tumor shrinkages) be used as a measure of therapeutic success? Treating cancer with chemotherapy is like treating alcoholism with vodka or treating diabetes with sugar.
Virtually all of the anticancer drugs approved by the FDA are toxic at the applied dosages and markedly immunosuppressive, destroying a patient’s natural resistance to many diseases, including cancer. Most of these FDA-approved chemo drugs are also carcinogenic, that is, capable of causing cancer in human beings.
All these drugs are poisonous not as a side effect but as a primary effect. Because these poisons cannot distinguish between cancerous and normal cells, they disrupt and kill normal, healthy cells throughout the body besides attacking tumors. They also significantly damage the bone marrow, thereby destroying the white blood cells, which fight infection; the red blood cells, which carry life-sustaining oxygen to the body’s organs; and the platelets, which help the blood to clot.
The true situation is that ineffective, aggressive chemotherapy can diminish not just quality of life but also quantity of life through organ toxicity, immunosuppression, and by inducing mutations in genetically unstable tumor cells to more aggressive phenotypes. The result is no significant improvement in the treatment of the most common forms of cancer over the past several decades.
Cancer is not caused by a poison deficiency, and poisoning the body while calling it “treatment” is a prime example of deception.
Don’t believe the hype!
There is no cure for our addiction to medical hype. We want to believe that this “breakthrough” will work for us. We may even want our mother enrolled in this special “clinical trial”, or a new chemo protocol with “state-of-the-art” drugs. Don’t be fooled. It isn’t therapeutic efficacy, but ego and greed that determine what cancer treatment options are available to the vast majority of patients, and we will demonstrate the evidence here to prove our viewpoint. We know you want a cure, just realize that chemotherapy is extremely unlikely to provide it.
You want to believe your Doctor. You want to believe in his recommendations. But when you cling to an unsubstantiated belief like chemotherapy, that’s not science. It’s dogma. When medical interventions are guided by dogma rather than solid scientific data, then health science policy has gotten ahead of health science. Such is the state of modern medicine.
Here is where the rubber meets the road, and documentation beats conversation. Please read on.
“At a time of universal deceit –telling the truth is a revolutionary act.” – George Orwell.
Chemotherapy as a choice for treating and curing cancer has a scientifically documented failure rate of 97%. Spontaneous remission may have a better success rate. This may be a shock to you and cause you to say: “That is ridiculous! If that was true, why weren’t we told this by our oncologist?”
For those who claim this is nonsense, we refer you to the following research. The first confirms the 97% failure rate. In the November 1985 Scientific American Volume 253, Number 5, Pages 51-59 in the Article Entitled: The Treatment of Diseases and The War Against Cancer, by Dr. John Cairns, M.D. of Harvard University: on page 59 the following is printed: “… All told, adjuvant treatments now avert a few thousand (perhaps 2 or 3 percent) of the 400,000 deaths from cancer that occur each year in the U.S.” It also states, “Aside from certain rare cancers, it is not possible to detect any sudden changes in the death rates for any of the major cancers that could be credited to chemotherapy. Whether any of the common cancers can be cured by chemotherapy has yet to be established.”
The British Medical Journal, demonstrated nearly the same figure a year later in the article, Cytotoxic chemotherapy for common adult malignancies: “the emperor’s new clothes” revisited? (Clinical Resource Edition). Oct 4, 1986; 293(6551): 871–876. By: J H Kearsley “Treatment of the most common adult tumours by cytotoxic chemotherapy is still disappointing…Estimated number of people who benefit from chemotherapy in the United States.–“3.18% (25,000) Achieve appreciable prolongation of life (>2 years).” The contribution of chemotherapy to overall survival in the USA was estimated to be only 4.3%. “it can be argued that cancer chemotherapy should not be made available widely in the community because of its limited efficacy and significant morbidity.”
Dr. Ulrich Abel, Ph.D., the highly published and respected German Professor, biostatistician and epidemiologist from the University of Heidelberg sent the cancer industry into a frenzy with his 1990 book, Chemotherapy of Advanced Epithelial Cancer: A Critical Survey, published by Hippokrates Verlag Stuttgart, 1990. This work is a comprehensive analysis of over 3,000 worldwide clinical trials and data from nearly 350 cancer experts and cancer centers from around the world on the value of chemotherapy for cancer treatment. Dr. Abel shows that chemotherapy alone can help only about 3% of the patients with epithelial cancer (such as breast, lung, colon and prostate) which kills 80% of all cancer patients. The release of his book was such a sensation, that Der Spiegel, Europe’s highest-circulating news magazine with over one million copies sold every week, featured a story about it. A condensed review was as well published in 1992 in the French medical journal Biomed Pharmacother entitled “Chemotherapy of advanced epithelial cancer: a critical review”, Vol. 46, no. 10, pages: 439 -452 (1992). In this well known medical journal, Dr. Abel makes the following irrefutable revelations;
“Many oncologists take it for granted that response to therapy prolongs survival, an opinion which is based on a fallacy and which is not supported by clinical studies.”
“There is no direct evidence that chemotherapy prolongs survival of breast cancer patients.”
“…a sober and unprejudiced analysis of the literature has rarely revealed any therapeutic success by the [chemotherapeutic] regimens in question.”
He concluded that “for most internal cancers no proof exists that chemotherapy, especially the increasingly high dose variety, increases life expectancy or improves quality of life.”
Documentation Dr. Abel cancer study
DocumentationDr. Abel DER SPIEGEL ARTICLE
Documentation Dr. Abel DER SPIEGEL ARTICLE text English and German
Documentation Dr. Abel key points summary in GERMAN
Documentation Dr. Abel key points summary in ENGLISH
Documentation Additional published works of Dr. Abel
A recent search turned up exactly zero reviews of his work in American journals. Our belief is that this is not because his work was unimportant – but because it’s irrefutable.
The 97% ineffectivity of chemotherapy has even been noted in the Journal of the National Cancer Institute, as part of the article; Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis, appearing in the September 15, 1993 issue; Volume 85 (No. 18): pages 1460-74, by Smith, Hillner, and Desch. This is one of many clinical articles that shows what’s going on behind the smoke and mirrors of modern oncology. “Many cancer treatments are, unfortunately, ineffective. Cancer mortality rates have not changed substantially in the past decade, despite a ‘War on Cancer’…chemotherapy results in a durable response in only 4% of patients and substantially prolongs the life in only an additional 3% of patients with advanced cancers.”
In a stunning 1994 radio interview, internationally renowned cancer researcher Dr. Ralph Moss, Ph.D., related that chemotherapy was effective in only 2 to 4% of all malignancies (Hodgkin ’s disease, Acute Lymphocytic Leukemia, childhood leukemia, testicular cancer and Choriocarcinoma.) Here is a brief excerpt;
Laura Lee: When you look at the statistics, chemotherapy is a standard treatment for all types of cancer generally speaking.
Dr. Moss: Yes, it has become.
Laura Lee: However, when you really look at the statistics, you were saying, only a few respond.
Dr. Moss: Yes, 2-4%
Laura Lee: How in the world, Dr. Moss, can it be considered a standard cure, when it works for 2-4%, and very specific ones?
Dr. Moss: We are dealing with an industry. It is not supported by the facts.
Alive Magazine, The Failure of Chemotherapy, By Dr. Zoltan Rona, M.D., M.Sc., March 2000. “Well over 50 percent of all cancer patients receive chemotherapy, yet these relatively toxic drugs help only five percent of these cases.”
“For all adult onset cancers, chemotherapy is 97% ineffective.”
Dr. Peter Glidden, (2010) The MD Emperor Has No Clothes: Everybody is Sick and I Know why.
Let’s move forward in time and see that surely there must be a dramatic improvement after several more years right? Unfortunately…Not.
In 2004, a landmark study by Australian researchers came to the same conclusion of a 97% failure rate of chemotherapy. Oncologists and clinical researchers, Dr. Graeme Morgan, from the Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Dr. Robyn Wardy, from Department of Medical Oncology, St Vincent’s Hospital, Sydney, and Dr. Michael Bartonz, from Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Health Service, Sydney, Australia undertook an extensive meta-analysis regarding the efficacy of chemotherapy on the five year survival of cancer patients entitled: The Contribution of Cytotoxic Chemotherapy to 5-year Survival in Adult Malignancies. Their conclusion based on facts amassed by significant worldwide research was published in 2004 in the peer reviewed medical journal Clinical Oncology, Volume 16, pages 549 -560. “Results: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA. … Conclusion … To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost effectiveness and impact on quality of life is urgently required. …”
Dr. Morgan was interviewed after the release of this explosive report on ABC news.
Australia Broadcast News Interview with Dr. Graeme Morgan by Dr. Norman Swan on The Health Report: 18 April 2005 – Chemotherapy. Here is a very brief excerpt. The full transcript is below.
Norman Swan: What were your findings?
Graeme Morgan: Well the findings were that in Australia that the five year survival due to chemotherapy was 2.1% of the total cancers.
Norman Swan: You mean the additional survival benefit?
Graeme Morgan: Yeah, from the chemotherapy.
Full transcript here and here
Later in the program, Associate Professor Dr. Michael Boyer, Head of Medical Oncology at the Sydney Cancer Centre at Royal Prince Alfred Hospital disagreed. Here is a small excerpt of his exchange.
Norman Swan: But I mean a 2% additional survival does not sound impressive.
Michael Boyer: Well it doesn’t sound impressive and it’s also not correct. It’s not correct for a number of reasons. That 2% figure is achieved by including a whole series of diseases in which chemotherapy would never be used. The paper itself actually states that yet they are included as part of the denominator if you like. So if you start taking those things out and saying well OK, how much does chemotherapy add in the people that you might actually use it, the numbers start creeping up. If you pull it altogether that number probably comes up to 5% or 6%, I guess what’s important is that it doesn’t go up to 50% or 60% but we know that and we know that these treatments are at the margin.
Full transcript here and here
If the best defense of chemotherapy that orthodox oncology can come up with is that it may actually be effective for 5 or 6 percent of cancer patients, rather than merely 2 to 3 percent, then surely it is high time for a radical reassessment of the widespread use of this toxic modality in cancer treatment, isn’t it?
Dr. Eva Segelov, M.D., addressed the study and the considerable fallout from the ABC News radio show.
Australian Prescriber, 2006, Vol. 29, No. 1, pages 2-3
The emperor’s new clothes – can chemotherapy survive?
By: Dr. Eva Segelov M.D., Medical Oncologist, St Vincent’s Clinical School, Sydney, Australia.
“We are still left with the finding that the overall contribution of cytotoxic chemotherapy to survival in the 22 cancers reviewed in the study is less than 3%…At 2% or 6%, surely the message is the same.”
“Approximately 2% of patients with disseminated or metastatic cancer treated with chemotherapy will be cured of their disease and prolongation of survival is not feasible for most patients afflicted by most types of cancer.”
Dr. Guy Faguet (2006). The war on cancer: An anatomy of failure, a blueprint for the future. Dordrecht: Springer.
British Journal of Cancer, 2004, 90, 1120 – 1124
Molecular profiling of breast cancer: clinical implications, by: S. Cleator and A. Ashworth
“At present, the majority of premenopausal women with node-negative breast cancer receive adjuvant chemotherapy, but the absolute survival benefit from treatment (proportion cured by the use of chemotherapy) is only around 3% at 5 years…”
Alive Magazine, Chemotherapy The 2-percent solution, By David Crowe, November 2006. “In 1948 experiments with chemotherapy for lung cancer resulted in a response in about half of the patients, but a median lifespan of only five months. Fifty years later a large trial reported a smaller response rate (16 to 21 percent) with four different chemotherapy regimens but a slightly longer median survival of about eight months. This illustrates both the lack of correlation between response and survival rates and the minimal progress that has occurred in half a century… chemotherapy only makes a minor contribution to cancer survival; this treatment is responsible for just over 2 percent of cancer patients surviving for five years…It is plausible, then, to conclude that chemotherapy provides almost no overall benefit.”
Science Based Medicine, 2008, March 24
When impressive science fails to impress patients, By: Dr. David H. Gorski, MD, PhD, FACS.
“In the case of stage I breast cancer, for example, the absolute survival benefit due to adjuvant chemotherapy is on the order of 3%.”
Medscape, August 5, 2004. Adjuvant Therapy for Stage II Colon Cancer: A Review of Clinical Practice Guidelines By: Dr. John S. Macdonald, M.D.
“…there is no statistically significant survival benefit for adjuvant chemotherapy.”
Annales De Chirurgie, 1998; 52(8):711-5
Mesure de la qualité de vie durant une chimiothérapie adjuvante du cancer colorectal
By: Bellemare et al.
“Despite the US National Institutes of Health consensus statement endorsing chemotherapy, many clinicians regard such a seemingly small benefit not worth the expense, inconvenience, discomfort and risk of treatment for their individual patient…
Newsweek 10/23/09- Dr. Otis Webb Brawley, M.D., Chief medical officer of the American Cancer Society
“…only some leukemias, lymphomas, and testicular cancers can be cured with chemotherapy…”
► Percentage of cancer patients whose lives are predictably saved by chemotherapy – 3%
► Conclusive evidence (majority of cancers) that chemotherapy has any positive influcence on survival or quality of life – none.
► Percentage of oncologists who said if they had cancer they would not participate in chemotherapy trials due to its “ineffectiveness and its unacceptable toxicity” – 75%
► Percentage of people with cancer in the U.S. who receive chemotherapy – 75%.
From Reclaiming Our Health: Exploding the Medical Myth By: John Robbins. ISBN 0915811804 (ISBN13: 9780915811809)
Cancer patients who do NOTHING to treat their cancer can have far better success rates than 3%. In the following recent study, as many as 22% of invasive breast cancers in Norwegian women disappeared spontaneously.
Archives of Internal Medicine, 2008; 168(21):2311-2316.The Natural History of Invasive Breast Cancers Detected by Screening Mammography, By: Per-Henrik Zahl, MD, PhD; Jan Mæhlen, MD, PhD; H. Gilbert Welch, MD, MPH.
In two study groups of 100,000 women, more than one in five invasive cancers detected in the study by mammography vanished without ever being treated!
Dartmouth University story
The New York Times, “Study Suggests Some Cancers May Go Away”
Dr. Barnett Kramer, M.D., M.P.H., director of the Office of Disease Prevention at the National Institutes of Health, is quoted in the article saying, “People who are familiar with the broad range of behaviors of a variety of cancers know spontaneous regression is possible, But what is shocking is that it can occur so frequently.”
Newsweek 10/23/09- Dr. Otis Webb Brawley, M.D., Chief medical officer, American Cancer Society
“We’re finding that about 25 to 30 percent of some cancers stop growing at some point,” Brawley says. ”That can make some treatments look good that aren’t doing anything. Until doctors figure out how to identify which patients have cancers that won’t progress,” he said, “the only option is to treat everyone.”
Studies show that being married is more effective for a patient than chemo!
Journal of Clinical Oncology, 2013, Vol. 31, No. 31, pages: 3869-3876
Marital Status and Survival in Patients With Cancer, By: Aizer et al
“For five cancers studied (prostate, breast, colorectal, esophageal, and head/neck cancers), the survival benefit associated with marriage was larger than the published survival benefit of chemotherapy.”
Journal of Clinical Oncology, 2013, Vol. 31, No. 31, pages: 3852-3853
Marriage Is As Protective As Chemotherapy in Cancer Care
By: Dr. David W. Kissane, MD, MPM, FRANZCP, FRAChPM
“Strikingly, the benefits of marriage are comparable to or greater than anticancer treatment with chemotherapy.”
“The further a society drifts from truth the more it will hate those who speak it.” – George Orwell
Journal of Pathology, 2005; 205: 275–292
Molecular mechanisms of drug resistance, By DB Longley and PG Johnston, Drug Resistance Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, N Ireland, UK
“Resistance to chemotherapy is believed to cause treatment failure in over 90% of patients with metastatic cancer, and resistant micrometastic tumour cells may also reduce the effectiveness of chemotherapy in the adjuvant setting.”
The Lancet, Medical oncology in the 1990s, Vol. 337, No. 8746, p 901–902, By: Dr. Albert Braverman, M.D., Professor of Hematology and Oncology at the State University of New York, Brooklyn, wrote “The time has come to cut back on the clinical investigation of new chemotherapeutic regimens for cancer and to cast a critical eye on the way chemotherapeutic treatment is now being administered…No disseminated neoplasm (cancer) incurable in 1975 is curable today…Many medical oncologists recommend chemotherapy for virtually any tumor, with a hopefulness undiscouraged by almost invariable failure.”
Also quoted in Wellness, March 2008, Vol. 23, No. 1, pages 5-6.
“Many cancer patients mistakenly believe chemotherapies will cure them, new study says”
Boston Globe 10/24.2012
“The issue here isn’t really over-optimism, but instead thinking that a treatment offers a chance of cure when in fact it doesn’t.” -Dr. Jane Weeks, director of the McGraw/Patterson Center for Population Sciences at Dana-Farber
The New England Journal of Medicine, 2012; 367:1616-1625
Patients’ Expectations about Effects of Chemotherapy for Advanced Cancer
By: Weeks et al. “Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative.” It continues with,“Should we be concerned that the majority of patients with these diseases provide responses suggesting that they do not understand that there is essentially no chance that the chemotherapy they are receiving will cure them?”
*The study leader, Dr. Jane Weeks, M.D., M.Sc. was director of the McGraw/Patterson Center for Population Sciences at Dana-Farber, and also taught at Harvard Medical School and the Harvard School of Public Health. She died of cancer on Sept. 10, 2013 in her Boston home. She was 61.
American Cancer Society, Cancer Facts & Figures 2007
“Surgery, radiation therapy, and chemotherapy are treatment options that may extend survival and/or relieve symptoms in many patients, but seldom produce a cure.”
The New England Journal of Medicine, 2011; 364:2060-2065
Bending the Cost Curve in Cancer Care. By: Dr. Thomas J. Smith, M.D., and Dr. Bruce E. Hillnrer, M.D. “Most patients with cancer have unrealistically optimistic expectations regarding their prognosis and response to therapy…Resetting expectations will be difficult. Tools are available to help the oncologist provide truly informed consent by sharing anticipated response rates, chances of cure (always near zero for patients with metastatic solid tumors), and side effects…”
Annals of Oncology, 2006, 17 (Supplement 10): x315–x324,
Chemoresistance in solid tumours, By T. R. Wilson, D. B. Longley & P. G. Johnston
Drug Resistance Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland
“Drug resistance is a major factor that limits the effectiveness of chemotherapy. Tumours can be intrinsically resistant prior to chemotherapy, or resistance may be acquired during treatment by tumours that are initially sensitive to chemotherapy. Furthermore, in the process of acquiring resistance, the tumour may become cross-resistant to a range of chemotherapies and result in resistance, which ultimately leads to treatment failure in over 90% of patients with metastatic disease.”
“Unfortunately, for four of the most common kinds of cancer (colon and rectum, pancreas, stomach and most kinds of lung cancer) there is no convincing evidence that chemotherapy offers any benefit whatsoever. Cancer researchers, medical journals, and the popular media all have contributed to a situation in which many people with common malignancies are being treated with drugs not known to be effective.” – Dr. Martin Shapiro, M.D., of UCLA in the Los Angeles Times article ‘Chemotherapy: Snake-Oil Remedy?’
British Medical Journal, 1995, 310:246-8
Chemotherapy for solid tumours. Routine treatment not yet justified. By: G.M. Mead
“most cancers are incurable once metastatic and often respond poorly to chemotherapy, which can result in side effects, inconvenience, and financial costs without improvements in symptoms or survival.”
Prospect Magazine, February 2002, Issue #71
A new strategy for cancer, By: Dr. Michael Baum, M.D., Professor Emeritus of Surgery and visiting Professor of Medical Humanities at University College London
“The advent of genetic medicine has so far made little difference in the battle against cancer. In fact, despite advances in treating leukaemia and breast cancer, little overall progress has been made since the early 1970s. A new strategy is needed… Instead of the reductio ad absurdum [reduction to absurdity] of persisting with high dose chemotherapy to virtually lethal doses, we should try to understand why rare cancers respond to chemotherapy but common solid cancers do not.”
In April 2004, Der Spiegel, Europe’s highest-circulating news magazine with over one million copies sold every week, printed a hard-hitting exposé of chemotherapy titled Giftkur ohne Nutzen, [Useless Poisonous Cures]. One of the many significant quotes comes from Dr. Wolfram Jaeger, M.D., Director of Gynecology at the State Clinics of Düsseldorf. He states, “Chemotherapy gave, and gives, no successes. Enormous numbers of women are treated, without any proven benefit. If we told this to our patients, however, they would totally despair.”
Journal of the American Medical Association, 1992;267(16):2191-2196 By: Johansson et al. High 10-Year Survival Rate in Patients With Early, Untreated Prostatic Cancer. This study in the Journal of the American Medical Association of 223 patients concluded that no treatment at all for prostate cancer actually was better than any standard chemotherapy, radiation or surgical procedure.
Proceedings of The National Academy of Sciences, Vol. 95, pp. 2094 –2099, March 1998
Codominant interference, antieffectors, and multitarget drugs
By: Dr. Alexander Varshavsky, Ph.D., Professor, California Institute of Technology.
“The main reason for the failure of cytotoxic therapies is their insufficient selectivity for tumors.”
The Ecologist, Vol 28 No 2 – March / April 1998, pages 117-121
The Diversity and Effectiveness of Natural Cancer Cures, By: Walter Last
“After analysing cancer survival statistics for several decades, Dr. Hardin Jones, Professor at the University of California,concluded in 1975 that “patients are as well, or better off untreated.” Jones’ disturbing assessment has never been refuted. What’s more, three studies by other researchers have upheld his theory.”
The current state of affairs in chemotherapy as “carpet-bombing therapeutics” is reported by Dr. David G. Nathan, M.D., President Emeritus, Dana Farber Cancer Institute at Harvard Medical School. Dr. Nathan penned THE CANCER TREATMENT REVOLUTION, in the TRANSACTIONS OF THE AMERICAN CLINICAL AND CLIMATOLOGICAL ASSOCIATION, VOL. 118, 2007.
“The three decades of clinical research carried out between 1955 and 1985 were largely devoted to the discovery and clinical trials of combinations of DNA-damaging agents that might best be described as carpet-bombing therapeutics. Great strides were made with these agents in certain diseases such as the hematological malignancies (particularly childhood leukemia), Hodgkin’s lymphoma, and the malignancies of the head and neck, colorectum, ovaries and testes and, to a certain extent, breast cancer. But the major epithelial cancers, including lung, colon and prostate, remain largely recalcitrant [not responsive to treatment]. Melanomas, pancreatic, hepatic, and brain cancers and most sarcomas are also generally unresponsive, while the toxic/therapeutic ratios of the broadly active carpet-bombing drugs are problematic. A new paradigm [system] is sorely needed.”
Annals of Internal Medicine, 1993;118(8):630-632.
Chemotherapeutic Failure: Resistance or Insensitivity? By: Dr. Albert S. Braverman, M.D.,
“While chemotherapy has been useful in treating some cancers – lymphomas and some acute leukemias – it cannot cure most cancers. Many attribute chemotherapy’s ineffectiveness to the high rate of cancer cell mutations and the selection of drug insensitive cells.”
“Practicing physicians are intimidated into using regimes which they know do not work. One of the most glaring examples is chemotherapy… but chemotherapy does not work for the majority of cancers… Most physicians agree that chemotherapy is largely ineffective for the majority of cancers.” Dr. Alan S. Levin, M.D., professor of immunology at the University of California Medical School in San Francisco, from “Corruption in American medicine”, in Dissent in Medicine – Nine Doctors Speak Out, The New Medical Foundation, 36th Floor, 115 South LaSalle Street, Chicago, Illinois 60603, publ. by Contemporary Books, Chicago, pp. 77-84.
Columbia College Record
British Journal of Cancer, 2000, 82 (7), 1254–1260
A randomized trial of treatment for stage one multiple myeloma by Riccardi and colleagues showed no advantage of conventional chemotherapy over no treatment at all.
Breast Cancer Research, 2004, 6:R372-R374
Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. By Retsky et al.
“After the primary tumor is resected, the angiogenic switch is thrown and the lung metastases start to grow rapidly...it may be said that results of adjuvant chemotherapy have plateaued.”
Cancer Biology & Therapy, February 2005, 4:2, 252-254
Changing winds in the war on cancer, By: Dr. Eugene W. Gerner, Ph.D., Professor of Cell Biology & Anatomy, University of Arizona.
“I became discouraged by our apparent inability to objectively increase survival or decrease mortality rates for patients afflicted with the most common cancers (i.e., lung, colon, breast, prostate).”
The Lancet, 2013 Editorial “The failure of cancer medicine?”, in Volume 381, Issue 9865, Page 423, February 9, 2013 makes some startling statements. Respected oncologist, Dr. Franco Cavalli, M.D., says, “Current strategies to control cancer are demonstrably not working.” It continues with, “Worldwide cancer diagnoses and deaths are increasing. 8 million people died from cancer in 2010, a 38% increase compared with 1990. Cancer diagnoses are estimated to double by 2030.” It concludes with “has cancer medicine failed patients? In the words of cancer experts, the answer is yes.”
The Lancet, 2014; 383: 558–63
Rethinking the war on cancer, By: Prof. Douglas Hanahan, Ph.D., Swiss Institute for Experimental Cancer Research.
“The war on cancer has largely focused on mutant cancer cells, via chemotherapy and radiotherapy and, more recently, targeted therapy based on knowledge of the driver mutations that force the chronic proliferation that is the basis of the disease. Most of the time, however, cancers eventually find ways to circumvent such targeted strikes, adapting and then reemerging as expansive and often more aggressive growths…targeted therapies are generally not curative or even enduringly effective, because of the adaptive and evasive resistance strategies developed by cancers under attack.”
Australian Prescriber, 2006, Vol. 29, No. 1, page 2
“Chemotherapy is an accepted treatment for cancer, but how many patients are aware of its very limited effect on survival?”
British Medical Journal, 1992, 304:1523-1524
Cancer chemotherapy and quality of life, by: Dr. Michael Byrne, M.D.
“Chemotherapy may be offered, however, as treatment for advanced cancers of the gastrointestinal tract, lung, or breast -in which the prospect of cure is slight. In these circumstances a decision for or against treatment must be based on the probability of achieving palliation. By definition, palliative chemotherapy ought to improve the quality of life of a patient with cancer; yet evidence that it does so is often difficult to find.”
The Lancet, 2014; 383: page 1883, The war on cancer: time for a new terminology.
By: Dr. Ian Haines, M.D., Senior Medical Oncologist and Palliative Care Physician, Melbourne Oncology Group, Cabrini Medical Centre. Adjunct Clinical Associate Professor & Senior Medical Oncologist and Palliative Care Physician at Monash University
“The misplaced battlefield analogy has led to 40 years of toxic and overly aggressive chemotherapy in incurable solid cancers for which no studies have shown that maximum tolerated doses of chemotherapy achieve longer survival or better quality of life than do minimum effective doses.”
The National Confidential Enquiry into Patient Outcome and Death (NCEPOD) 2008 report found that more than four in ten patients who received chemotherapy suffered potentially fatal effects from the drugs, and treatment was “inappropriate” in nearly a fifth of cases.
BBC News– Doctors ‘rely on chemo too much’
ABC News- ‘Chemotherapy contributes to a quarter of cancer deaths: study’
Lancet Oncology, 2016; 17: 1203–16
30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. By: Wallington et al.
This landmark study found that up to 50 percent of people who receive chemotherapy are killed by the treatment, and not cancer.
The Telegraph, Aug. 30, 2016- “Chemotherapy warning as hundreds die from cancer-fighting drugs”
Express, Aug. 31, 2016- “Chemotherapy WARNING: Hundreds die from cancer drug treatment”
Aren’t Chemo drugs supposed to help you survive cancer? Someone should tell the FDA that…
Journal of Clinical Oncology, 2003; 21: 1404-1411
End Points and United States Food and Drug Administration Approval of Oncology Drugs
By: John R. Johnson, Grant Williams, and Richard Pazdur
“End points other than survival were the approval basis for 68% (39 of 57) of oncology drug marketing applications granted regular approval and for all 14 applications granted accelerated approval from January 1, 1990, to November 1, 2002.”
York University– “Quick cancer drug approvals don’t benefit patients: York U researcher”
The January 10, 2002 issue of The New England Journal of Medicine, Vol. 346, No. 2, in the editorial entitled: LUNG CANCER— TIME TO MOVE ON FROM CHEMOTHERAPY, it states “During the past 20 years, numerous efforts have been made to reduce the death rate among patients with lung cancer. Yet after 20 years, the improvement in long-term survival has been slight…the benefits of combination chemotherapy among the fittest patients with advanced non–small-cell lung cancer are marginal (with perhaps a gain in median survival of two to three months)…Chemotherapy in advanced lung cancer has reached a plateau; there are few differences among various combinations of drugs.” and lastly “The current treatment of advanced small-cell and non–small-cell lung cancer with combination chemotherapy is nonspecific, nonselective, and toxic. New combinations of chemotherapy are not likely to make substantial improvements in survival. 20 years of chemotherapy clinical trials on advanced lung cancer have yielded survival improvement of only two months.”
British Journal of Cancer, 2005; 93, 504 – 509
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. By: G. Apolone, R. Joppi, V. Bertele and S. Garattini.
This review of drugs for solid cancers approved by the European Medicines Agency (EMA) in its first 10 years found that, overall, new oncology drugs improved survival by a mean and median of only 1.5 and 1.2 months, respectively.
British Medical Journal, 2015 Apr 23;350:h2068
Why do cancer drugs get such an easy ride? By: Prof., Dr. Donald Light, Ph.D., and Prof., Dr. Joel Lexchin, M.D.
“71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression-free and overall survival of only 2.5 and 2.1 months, respectively,” said Dr. Joel Lexchin, one of the study’s co-authors who examined a wealth of earlier research to make these determinations. “Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee’s criteria for meaningful results for patients.”
Journal of the National Cancer Institute, 2009; Vol. 101: 1044–1048
How Much Is Life Worth: Cetuximab, Non – Small Cell Lung Cancer, and the $440 Billion Question. By: Dr. Tito Fojo, M.D., Ph.D., and Dr. Christine Grady, Ph.D.
“What should count as a benefit in cancer? What is the minimum amount of benefit needed to adopt a therapy as the new standard? Is 1.2 months of additional life a “good” in itself? How much should the quality of that 1.2 months matter? Or the cost?…Trials that demonstrate no survival advantage or prolonged survival of only 1 or 2 months should be subject to greater scrutiny.”
The New York Times reports in the April 24, 2009 edition in the article, Advances Elusive in the Drive to Cure Cancer that “the death rate for cancer, adjusted for the size and age of the population, dropped only 5 percent from 1950 to 2005.” It also notes “Still, the perception, fed by the medical profession and its marketers, and by popular sentiment, is that cancer can almost always be prevented.” Dr. Leonard Saltz, a colon cancer specialist at Memorial Sloan-Kettering Cancer Center states “People too often come to us expecting that the newest drugs can cure widespread metastatic cancer. They are often shocked to find that the latest technology is not a cure…It turns out that, with few exceptions, mostly childhood cancers and testicular cancer, there is no cure once a cancer has spread. The best that can be done is to keep it at bay for a while.” Dr. Saltz also noted that “It would be very hard and insensitive to say, ‘All I’ve got is a drug that will cost $10,000 a month and give you an average survival benefit of a month or two.”
The 5-year survival rate of cancer patients is the most commonly used statistic to reflect improvements in the war against cancer. Let’s see if that standard is valid.
Journal of the American Medical Association, June 14, 2000 Vol. 283 No.22: (2975-2978) in the article, Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? It breaks down the truth from fiction regarding 5 year survival and mortality.
“Although the expectation might be that large increases in 5-year survival would be associated with declining mortality (ie, a negative correlation), no obvious relationship is evident.” It also notes…”the increase in 5-year survival over time had little relationship to changes in the mortality from cancer…Nonetheless, improvements in 5-year survival are frequently presented to the public and to policymakers as proof that we are making progress against cancer.”
“Conclusion: Although 5-year survival is a valid measure for comparing cancer therapies in a randomized trial, our analysis shows that changes in 5-year survival over time bear little relationship to changes in cancer mortality. Instead, they appear primarily related to changing patterns of diagnosis.”
ABC News Australia reports on a study of 600 chemotherapy patients in the UK, “The review of 600 cancer patients in the UK who died within 30 days of chemotherapy treatment has found that one in four of the deaths was either caused or hastened by the treatment. “
Oncology Times, Vol. XXVI, No. 15, PAGE 7 / AUGUST 10, 2004
Dr. George A. Omura, M.D., Oncologist, on Giving, and Not Giving, Chemotherapy.
“The cancer chemotherapist gives chemotherapy; the medical oncologist should know when not to give it.”
BMC Palliative Care, 2011 Sep 21;10:14
The effect on survival of continuing chemotherapy to near death. By: Saito et al.
“Receipt of chemotherapy was associated with a 2-month improvement in overall survival.”
In this study, patients who received chemotherapy within 2 weeks of their death did not survive longer than those whose chemotherapy was discontinued earlier.
2013 San Antonio Breast Cancer Symposium, presentation by Dr. Rajendra Badwe, M.D., “Patients With Metastatic Breast Cancer May Not Benefit From Surgery and Radiation After Chemotherapy.” [LRT refers to surgery and radiation treatments]
“We found that there was no difference in overall survival between those who received LRT and those who did not receive LRT,” explained Badwe. “Indeed, there was a 7 percent excess death rate in those who received LRT… surgical removal of the primary tumor bestows a growth advantage on metastases… We were unable to identify any subgroups that are likely to benefit from LRT.”
The study began with 350 women, 62%  were dead within 17 months.
Title: Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial.
The New England Journal of Medicine, April 13, 2000, Vol. 342 No. 15, p 1069-1078. Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer
By: E.A. Stadtmauer and Others
“…chemotherapy does not improve survival in women with metastatic breast cancer.”
Surgical Oncology Clinics of North America, 12 (2003) 127–134.
Are there indications for chemotherapy in hepatocellular carcinoma?
By: Dr. Philip J. Johnson, MD, FRCP, University of Birmingham, United Kingdom.
“HCC is widely considered to be chemotherapy resistant. Response rates for single-cytotoxic-agent chemotherapy, as assessed by conventional criteria, are low, and durable remission is rare.
Single-agent Adriamycin gives a response rate of around 15% to 20%, and with combination therapy, this figure rises to around 20% to 35%; however, there is no proven survival benefit.”
British Journal of Cancer, (2007) 97, 589 – 592
The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients, By: P Kolodziejczyk et al.
“In conclusion, preoperative chemotherapy with cisplatin and 5-FU can significantly reduce the incidence of ITC in patients with resectable gastric cancer. However, it was not associated with any clear survival benefit.”
Editorial in The Lancet, Volume 341, Issue 8841, 6 February 1993, Pages 343–344. Breast cancer: have we lost our way? The answer: Yes. This response was based on breast cancer mortality figures that have held steady for 50 years, despite the so-called war on cancer and billions of dollars in research. “If one were to believe all the media hype, the triumphalism of the profession in published research and the almost weekly miracle breakthroughs trumpeted by the cancer charities, one might be surprised that women are dying at all from this (breast) cancer.” It continues with, “Some readers may be startled to learn that the overall mortality rate from carcinoma of the breast remains static.“
SAMJ Lancet Reference
German Society for cancer
The New England Journal of Medicine, Dr. Thomas L. Dao, M.D., Roswell Park Memorial Institute Department of Breast Surgery, wrote, “Despite improved surgical techniques, advanced methods in radiotherapies, and widespread use of chemotherapies, breast cancer mortality has not changed in the last 70 years.”
Urologia Internationalis,1989; Vol. 44, No. 6, pages 338–345 Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. By: Yagoda A. · Bander N.H. Cornell University Medical Center “A review of 36 cytotoxic agents used singly in over 1,900 patients with renal cancer between 1983 and 1988 finds marginal antitumor activity, less than 5-10%.”
Nature Clinical Practice Oncology, 2005, 2, S30-S35
Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies
By: Dr. Steven Gore, M.D., – Professor of Oncology, Johns Hopkins University
“Given the overall failure of cytotoxic chemotherapy in the achievement of cures in MDS [myelodysplastic syndromes] and MDS-related AML [acute myeloid leukemia], the application of less toxic, biologically directed agents may represent a more promising approach to treatment.”
“If liberty means anything at all, it means the right to tell people what they do not want to hear.”-George Orwell.
Austral – Asian Journal of Cancer, Vol. 4, No.4, October 2005. Surgery: A New Candidate to Explain Breast Cancer Paradoxes? By: Riccardo Ponzone, M.D., Ph.D.
“…the principle of indiscriminate cell-kill by chemotherapy is a path that will take to nowhere…Furthermore, the “sleepy” attitude of single disseminated cells who early colonise distant organs through the lymphatic or vascular circulation, should discourage everyone from thinking that they can be eradicated with conventional chemotherapy.”
Breast Cancer Research & Treatment, (2011) 130:345–351
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era, by: IC Chen et al.
“Tumor response to systemic chemotherapy remains generally poor for MCB patients…According to our single-institute retrospective study, the response of MCB to systemic chemotherapy remains poor in the modern era.”
The Lancet, 1998; 352: 515–21. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. By: Rodenhuis et al. “Since high-dose adjuvant therapy did not even yield minimum evidence of a survival advantage over optimum conventional therapy and was associated with severe toxic effects, we strongly believe that this therapy should be given only in the setting of a randomised clinical trial.”
Acta Oncologica, 28:1, 29-33. Quality of Life During Chemotherapy in Non-Small Cell Lung Cancer
Patients, By: C. Fernandez et al.
“Clinical chemotherapy trials in advanced NSCLC have yielded varying results; partial response has usually been observed in less than 50% of the patients and in most studies enhanced survival has not been observed…Despite a relatively high response rate chemotherapy regimens containing cisplatin have, according to some observations, not obviously prolonged median survival and they are associated with considerable toxicity that may reduce quality of life.”
Blood, 2013, May 30, Volume 121, Number 22
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
By: 100 World Experts in Chronic Myeloid Leukemia
“If drug price reflects value, then it should be proportional to the benefit to patients in objective measures, such as survival prolongation…most anticancer drugs provide minor survival benefits, if at all.”
The New Yorker, Oct 20, 2013, The Cost of Living By Stephen S. Hall
“most anti-cancer drugs provide minor survival benefits, if at all.”
Some of the best evidence regarding the lack of effectiveness for chemotherapy comes from Medical Textbooks such as;
Medical Textbook- Essential Practice of Surgery: Basic Science and Clinical Evidence
2003 Springer-Verlag New York, Inc., 761 pages
By: Jeffrey A. Norton et al.
“Both radiation and chemotherapeutic agents have their greatest effects on dividing cells. The division of endothelial cells, fibroblasts, and keratinocytes is impaired in irradiated tissue, which retards wound healing.” page 84
“Numerous trials investigating the value of postoperative chemotherapy have been performed. These have been assessed by meta-analysis concluding that there is no benefit. For advanced-stage gastric cancers, chemotherapy may transiently reduce the tumor size. However, there has not been any demonstrable improvement in survival irrespective of the agents or combinations of drugs investigated.” Page 195
“Recent data suggest that locoregional control of tumor is enhanced by preoperative chemoradiation but that the majority of patients still succumb to systemic disease.” page 211
“The majority of patients with pancreatic cancer present with either locally advanced disease or metastases, making cure impossible at the present time.” page 211
“Radiation and chemotherapy appear relatively ineffective.” page 214
“…chemotherapy and radiation therapies are largely experimental efforts or directed at palliation.” page 229
“Unfortunately, radiation therapy has had no demonstrable effect on patient survival. The same conclusion currently applies to single and combination adjuvant chemotherapy.” page 232
“Resection is the best treatment for small-bowel adenocarcinoma. At present, there is no convincing evidence that adjuvant chemotherapy or radiation treatments are effec-tive.” page 262
Leiomyosarcoma and Malignant Stromal Tumors
“There is no evidence that adjuvant chemotherapy or radiation therapy alone or in combination is effective.” page 262
Metastatic Colorectal Cancer
“Systemic chemotherapy has not demonstrated dramatic or long-term effects.” page 305
“There is growing evidence that combined chemo–radiation therapy for Hodgkin’s lymphoma may be associated with a significantly increased risk of developing a second malignant disease.” page 328
“Stage IV disease is, for the most part, considered incurable and is treated with palliative chemotherapy and radiation.” page 516
“Without treatment of brain metastasis, the survival is only 1 month. Treatment of brain metastases with steroids palliates symptoms and extends the median survival to 2 months.” page 516
“Currently, mesothelioma continues to defy any single treatment modality including surgery, chemotherapy, and radiation therapy.” page 536
“Chemotherapy and radiation therapy are of no demonstrable benefit…” page 553
“Retrospective studies have not demonstrated any benefit to preoperative or postoperative doxorubicin-based chemotherapy for retroperitoneal sarcomas, and so the routine use of chemotherapy in these patients cannot be supported.” page 687
Head & Neck Cancer
“Data from many different trials do not demonstrate a survival advantage for use of chemotherapy for HNSCC (head and neck squamous cell carcinoma) in any setting compared to standard surgery and/or radiation therapy.” page 694
Here are some additional Doctors’ opinions:
“It is easy to see why it may be hard to distinguish the quacks from bona fide medical clinicians…Despite claims to the contrary, [cancer] treatment offers little more hope than it did a generation ago.”
Dr. Haydn Bush, M.D., London Regional Cancer Center in Canada, in Science September 1984
“Both chemotherapy and radiation have such toxic effects on the human body they must be stopped before they kill the patient.” Dr. Jim Howenstine, M.D.
“More people live off cancer than die from it.”
Dr. Deepak Chopra, M.D.
“All chemotherapy agents are carcinogenic.”
Dr. Russell Blaylock, M.D., Oncologist and Neurosurgeon
“We have a multi-billion dollar industry that is killing people, right and left, just for financial gain. Their idea of research is to see whether two doses of this poison are better than three doses of that poison.”
Dr. Glen Warner, M.D., Oncologist
“I look upon cancer in the same way that I look upon heart disease, arthritis, high blood pressure, or even obesity, for that matter, in that by dramatically strengthening the body’s immune system through diet, nutritional supplements, and exercise, the body can rid itself of the cancer, just as it does in other degenerative diseases. Consequently, I wouldn’t have chemotherapy and radiation because I’m not interested in therapies that cripple the immune system, and, in my opinion, virtually ensure failure for the majority of cancer patients.”
Dr. Julian Whitaker, M.D.
“There have been many cancer cures, and all have been ruthlessly and systematically suppressed with a Gestapo-like thoroughness by the cancer establishment. The cancer establishment is the not-too-shadowy association of the American Cancer Society, the leading cancer hospitals, the National Cancer Institute and the FDA. The shadowy part is the fact that these respected institutions are very much dominated by members and friends of members of the pharmaceutical industry, which profits so incredibly much from our professionwide obsession with chemotherapy.”
Dr. Robert C. Atkins, M.D., author, “Dr. Atkins New Diet Revolution” and founder, The Atkins Center in New York
“My studies have proved conclusively that untreated cancer victims live up to four times longer than treated individuals. If one has cancer and opts to do nothing at all, he will live longer and feel better than if he undergoes radiation, chemotherapy or surgery.”
Professor Hardin B. Jones, Ph.D., University of California
“Chemotherapy is a waste of money.”
Dr. Peter Glidden, N.D.
‘”In a given population of cancer cells in a person, maybe only 2% of the cancer cells possess a Pglycoprotein mediated pump’capable of pushing anti-cancer agents out of the cell before they can kill it. But it’s those 2% of cancer cells that eventually grow and expand to create drug resistant tumors.”
Dr. Jerry McLaughlin, Purdue University
“Most cancer patients in this country die of chemotherapy. It does not eliminate breast, colon or lung cancers. The fact has been documented for over a decade. Women with breast cancer are likely to die faster with chemotherapy than without it. This has been documented for over a decade and nevertheless doctors still utilize chemotherapy to fight these tumors.”
Dr. Alan Levin, M.D., University of California San Francisco Medical School, “The Healing of Cancer”, Marcus Books, 1990
“As a chemist trained to interpret data, it is incomprehensible to me that physicians can ignore the clear evidence that chemotherapy does much, much more harm than good.” Alan C. Nixon, Ph.D., Past President, American Chemical Society
“Every Doctor knows that chemotherapy causes cancer.”
Dr. Lorraine Day, M.D.
“In the end, there is no proof that chemotherapy in the vast majority of cases actually extends life, and this is the GREAT LIE about chemotherapy, that somehow there is a correlation between shrinking a tumor and extending the life of a patient.”
Dr. Ralph Moss, Ph.D.
“Except for two forms of cancer, chemotherapy does not cure. It tortures and may shorten life.”
Dr. Candace Pert, Georgetown University School of Medicine
“To sell chemotherapy as a “therapy” is most likely the biggest deceit in the history of medicine. Whoever masterminded this chemo-torture deserves a monument in hell.”
Dr. Ryke Hamer, M.D.
“Should I ever get cancer, I would never ever allow myself to be treated in a conventional cancer clinic. Only cancer victims who stay away from such centres would have a chance of survival.” Prof. Dr. Georges Mathé, M.D., Oncologist
“Finding a cure for cancer is absolutely contraindicated by the profits of the cancer industry’s chemotherapy, radiation, and surgery cash trough.”
Dr. John Diamond, M.D.
“Chemotherapy is an incredibly lucrative business for doctors, hospitals, and pharmaceutical companies…..The medical establishment wants everyone to follow the same exact protocol. They don’t want to see the chemotherapy industry go under, and that’s the number one obstacle to any progress in oncology.”
Dr. Glen Warner, M.D., Oncologist
“I tell you one thing boy, if your friend touches chemotherapy, he’s a goner.”
Dr. Ernst Wynder, M.D., renowed Epidemiologist
“I rarely see distant metastasis until after a biopsy — and then it rapidly goes everywhere including the bones.” Dr. Vincent Gammill
“For decades there has been a great deal of controversy within the medical community over what kind of medical treatment is most efficacious in treating cancer. Latest findings reveal all conventional medical treatment for cancer is virtually worthless.“
Dr. Hardin B. Jones, M.D. Professor of Medical Physics and Physiology at Berkeley
Therefore, does Chemo really make any sense?
If an elderly person had an injured toe and it needed a cold compress to help heal it, would you dunk them in a freezing tub of water repeatedly for days, and then wait for the toe to heal? This would damage the entire body trying to fix one small part. Doctors know how absurd the ideology of chemotherapy really is, but are coerced into suggesting it due to a variety of factors including income.